Follow us on:

Linkedin Facebook

GSK reaches confidential settlement with James Goetz in Zantac litigation

GSK

GSK plc (LON/NYSE: GSK) today confirmed it has reached a confidential settlement with James Goetz, and the case he filed in California state court, set to begin trial on July 24, 2023, will be dismissed.

The settlement reflects the Company’s desire to avoid distraction related to protracted litigation in this case. GSK does not admit any liability in this settlement and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases.

Share on:

Latest Company News

GSK Shingrex

GSK’s Shingrix Prefilled Syringe Approved in Europe

GSK has received European Commission approval for a prefilled syringe presentation of its Shingrix shingles vaccine.
GSK

GSK Plc receives China approval for Nucala in COPD treatment

GSK plc has announced that China’s National Medical Products Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with inadequately controlled COPD characterised by raised blood eosinophils.
GSK Plc

GSK Plc reaches US agreement to reduce prescription medicine costs

GSK has entered into an agreement with the US Administration to lower the cost of prescription medicines for American patients, including treatments across its respiratory portfolio for asthma and COPD.
GSK

GSK secures FDA approval for Exdensur in severe eosinophilic asthma

GSK plc has received US FDA approval for Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in patients aged 12 and over.
GSK plc

GSK Plc secures UK approval for Exdensur in asthma and nasal polyps

GSK has announced that Exdensur (depemokimab) has received marketing authorisation from the UK MHRA for use in certain asthma and chronic rhinosinusitis with nasal polyps patients.
GSK plc

GSK RSV vaccine recommended for wider adult use, CHMP backs expansion

GSK has announced that the EMA’s CHMP has recommended broadening the indication of its adjuvanted RSV vaccine to adults aged 18 and over, with a final decision expected in February 2026.

    Latest interviews

    View all interviews 

    Company Presentations

    View all Company Presentations

    BrokersTalk

    View all Broker Talk

    FTSE 100 News

    Search

    Search

    Green News

    View all Sustainable sectors, Plcs and news  

    Q&A's

    View all Question and Answers

    Funds

    View all Funds, Market Insights and news

    UK Broker Ratings

    Hardman & Co

    Don't Miss Our News Alerts

    Subscribe Free

    Find us on:

    Linkedin Facebook

    Follow us on Social Media:

    Home X-twitter Linkedin Facebook Spotify Apple